Business

Mass. Movers

Insiders boosting their stake in Aegerion

Aegerion develops drugs to treat rare diseases.
istockphoto.com
Aegerion develops drugs to treat rare diseases.
Advertisement

The Motley Fool, noting one way to forecast a stock’s direction is to monitor insiders’ share purchases, reported that Cambridge-based Aegerion Pharmaceuticals Inc. has seen “significant insider and institutional interest.” In the last 6 months, insiders have acquired an additional 624,767 shares, bringing total insider holdings to 5.8 million shares, an 11 percent increase. During the same time, institutions increased their holdings by 2.1 million shares, or 10 percent.